Your browser is no longer supported. Please, upgrade your browser.
CymaBay Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.74 Insider Own0.40% Shs Outstand68.92M Perf Week-10.66%
Market Cap265.12M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float65.19M Perf Month-8.37%
Income-51.00M PEG- EPS next Q-0.24 Inst Own82.40% Short Float13.05% Perf Quarter-35.52%
Sales- P/S- EPS this Y51.70% Inst Trans-0.17% Short Ratio8.52 Perf Half Y-53.65%
Book/sh2.07 P/B1.90 EPS next Y3.60% ROA-29.70% Target Price- Perf Year121.35%
Cash/sh2.17 P/C1.81 EPS next 5Y- ROE-31.90% 52W Range1.74 - 9.06 Perf YTD-31.36%
Dividend- P/FCF- EPS past 5Y2.10% ROI- 52W High-56.51% Beta1.22
Dividend %- Quick Ratio15.40 Sales past 5Y- Gross Margin- 52W Low126.44% ATR0.22
Employees44 Current Ratio15.40 Sales Q/Q- Oper. Margin- RSI (14)35.95 Volatility5.88% 5.24%
OptionableYes Debt/Eq0.00 EPS Q/Q46.60% Profit Margin- Rel Volume1.15 Prev Close4.17
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume998.45K Price3.94
Recom1.60 SMA20-9.31% SMA50-13.88% SMA200-35.20% Volume1,199,770 Change-5.52%
Aug-04-20Reiterated H.C. Wainwright Buy $9 → $13
Jul-31-20Initiated Piper Sandler Overweight $12
May-26-20Upgrade H.C. Wainwright Neutral → Buy $9
May-12-20Upgrade SVB Leerink Mkt Perform → Outperform $6
May-12-20Upgrade Stifel Hold → Buy $4 → $8
May-12-20Upgrade ROTH Capital Neutral → Buy $15
May-12-20Upgrade Raymond James Mkt Perform → Outperform $7
May-12-20Upgrade Evercore ISI In-line → Outperform $15
Mar-13-20Upgrade Oppenheimer Perform → Outperform $4
Mar-13-20Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-26-19Downgrade ROTH Capital Buy → Neutral $22 → $2
Nov-26-19Downgrade Raymond James Strong Buy → Mkt Perform
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral $16 → $2
Nov-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $20 → $2
Nov-25-19Downgrade SunTrust Buy → Hold
Nov-25-19Downgrade Stifel Buy → Hold
Nov-25-19Downgrade Evercore ISI Outperform → In-line
Jun-25-19Initiated Stifel Buy
Jun-12-19Upgrade Raymond James Outperform → Strong Buy
May-14-19Initiated Citigroup Buy $21
May-10-21 08:00AM  
May-06-21 08:00AM  
Apr-05-21 08:00AM  
Apr-01-21 02:15AM  
Mar-27-21 01:30AM  
Mar-25-21 04:10PM  
Mar-12-21 08:00AM  
Mar-11-21 08:00AM  
Feb-24-21 08:00AM  
Feb-10-21 08:00AM  
Jan-04-21 09:27AM  
Dec-31-20 11:25PM  
Dec-16-20 10:07PM  
Nov-16-20 04:01PM  
Nov-11-20 08:00AM  
Nov-07-20 02:01AM  
Nov-05-20 04:05PM  
Nov-02-20 08:00AM  
Oct-30-20 04:32PM  
Oct-01-20 08:00AM  
Sep-30-20 09:58AM  
Sep-29-20 11:21AM  
Sep-22-20 07:00AM  
Sep-03-20 04:05PM  
Aug-27-20 08:00AM  
Aug-20-20 08:00AM  
Aug-11-20 03:01AM  
Aug-10-20 04:01PM  
Aug-05-20 03:31PM  
Aug-03-20 04:01PM  
Jul-23-20 08:00AM  
Jul-13-20 03:05AM  
Jul-05-20 09:44AM  
Jun-28-20 07:20PM  
Jun-19-20 08:00AM  
Jun-18-20 08:45AM  
Jun-09-20 05:53PM  
Jun-05-20 05:00PM  
Jun-02-20 10:22AM  
Jun-01-20 08:34AM  
May-26-20 06:12PM  
May-21-20 07:21AM  
May-15-20 08:29AM  
May-13-20 09:37AM  
May-12-20 10:34AM  
May-11-20 04:01PM  
May-04-20 04:43PM  
Apr-02-20 04:01AM  
Mar-20-20 08:30PM  
Mar-13-20 05:29PM  
Mar-12-20 04:01PM  
Mar-11-20 07:00PM  
Mar-10-20 12:15PM  
Mar-09-20 07:51PM  
Mar-06-20 10:49AM  
Mar-05-20 07:00PM  
Mar-04-20 06:09PM  
Mar-03-20 03:12PM  
Mar-02-20 06:50PM  
Feb-28-20 09:52PM  
Feb-05-20 11:52AM  
Jan-29-20 04:15PM  
Jan-15-20 02:25PM  
Jan-10-20 09:21AM  
Dec-31-19 11:48AM  
Dec-17-19 10:31AM  
Dec-10-19 03:36PM  
Dec-09-19 06:09AM  
Dec-08-19 07:09PM  
Nov-29-19 11:24AM  
Nov-27-19 10:09AM  
Nov-26-19 11:07AM  
Nov-25-19 04:20PM  
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.